Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Core Insights - Legend Biotech will present significant data on CARVYKTI for multiple myeloma at the upcoming ASH Annual Meeting, showcasing the therapy's effectiveness and safety profile [1][3][5] - The company is also introducing first-in-human data for Lucar-G39D, a novel allogeneic CAR-T therapy for B-cell non-Hodgkin lymphoma [2][3] CARVYKTI Presentations - Two oral presentations and seven poster presentations will focus on CARVYKTI, emphasizing its long-term progression-free survival and immune fitness benefits [1][4] - CARVYKTI is the first BCMA-targeted CAR-T cell therapy approved for multiple myeloma, currently available in 14 countries and used to treat over 9,000 patients globally [3][4] Lucar-G39D Development - An oral presentation will detail the investigational Lucar-G39D therapy, which targets both CD20 and CD19 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma [2][7] - This therapy represents Legend Biotech's efforts to expand its pipeline into next-generation allogeneic cell therapies [3] Clinical Trials and Studies - The CARTITUDE-4 study is an ongoing Phase 3 trial comparing cilta-cel with standard therapies for relapsed and lenalidomide-refractory multiple myeloma [58] - The CARTITUDE-1 study evaluates cilta-cel's safety and efficacy in patients with advanced multiple myeloma who have undergone multiple prior therapies [59] Company Overview - Legend Biotech is a leader in cell therapy, focusing on innovative treatments for cancer, particularly through CAR-T therapies like CARVYKTI [63] - The company collaborates with Janssen Biotech for the development and commercialization of cilta-cel, which has received multiple regulatory designations and approvals [56][57]